FDA Approves New Indication for Delafloxacin for CABP
eMediNexus, 27 October 2019
remove_red_eye 502 Views
#Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Pulmonary Medicine
remove_red_eye 502 Views
#Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Pulmonary Medicine
The US Food and Drug Administration (FDA) has approved delafloxacin (Baxdela, Melinta Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria, according to a company news release.
This is the second indication for the fluoroquinolone antibiotic. Approval of delafloxacin for CABP was based on positive results from a phase 3, randomized, double-blind trial comparing the efficacy and safety of delafloxacin to moxifloxacin… (Medscape)
To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
